Antimicrobial PK in Infants With Suspected or Confirmed Infection
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this protocol is to provide a mechanism for the ongoing collection of blood
and urine samples in newborns that will be used to measure levels of antimicrobial products
used in the newborn population where there are limited pharmacokinetic data in either
premature or term infants.
Details
Lead Sponsor:
Duke University
Collaborator:
Pediatric Pharmacology Research Units Network
Treatments:
Acyclovir Amphotericin B Ampicillin Anidulafungin Anti-Infective Agents Caspofungin Liposomal amphotericin B Metronidazole Penicillanic Acid Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam